Cyramza (Ramucirumab) Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The cyramza (ramucirumab) market size has grown strongly in recent years. It will grow from $1.31 million in 2025 to $1.4 million in 2026 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to approval for gastric and colorectal cancers, rising global cancer burden, clinical success of vegfr inhibitors, hospital oncology adoption, limited late stage treatment options.

The cyramza (ramucirumab) market size is expected to see strong growth in the next few years. It will grow to $1.79 million in 2030 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to increasing incidence of solid tumors, expansion into new oncology indications, growth of targeted cancer therapies, rising oncology healthcare spending, improved diagnostic rates. Major trends in the forecast period include growing use of anti angiogenic therapies, expansion across multiple cancer indications, combination use with chemotherapy, rising demand in advanced stage cancers, hospital based oncology administration.

The growing incidence of cancer is anticipated to drive the expansion of the Cyramza (ramucirumab) market in the coming years. Cancer encompasses a group of diseases marked by uncontrolled cell growth and the ability to spread to other parts of the body. The increase in cancer cases is driven by factors such as an aging population, lifestyle habits, environmental exposures, advancements in diagnostic techniques, and genetic susceptibility. Cyramza (ramucirumab) is utilized in cancer therapy to specifically target and inhibit vascular endothelial growth factor receptor 2 (VEGFR-2), thereby restricting the formation of blood vessels that supply tumors and slowing disease progression. For instance, in August 2024, according to a report published by the Australian Institute of Health and Welfare, an Australia-based national authority on health and welfare statistics, Australia is expected to record around 209,000 new cancer diagnoses by 2034, compared with an estimated 169,000 cases in 2024, reflecting population growth and increasing cancer prevalence. Additionally, cancer is projected to account for nearly three out of every ten deaths in the country in 2024. Therefore, the rising incidence of cancer is contributing to the growth of the Cyramza (ramucirumab) market.

The increasing adoption of personalized medicine is expected to further support the growth of the Cyramza (ramucirumab) market going forward. Personalized medicine is a healthcare approach that customizes treatment and prevention strategies based on an individual’s genetic profile, lifestyle, and environmental factors rather than applying uniform therapies. The adoption of personalized medicine is accelerating due to advancements in genetic testing, which enable more precise treatment selection tailored to individual patient characteristics. Cyramza (ramucirumab) is applied within personalized medicine by targeting specific tumor pathways in patients whose cancers exhibit biomarkers responsive to VEGFR-2 inhibition. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, a notable increase from six approvals in 2022. As a result, the growing use of personalized medicine is driving the expansion of the Cyramza (ramucirumab) market.

The expanding aging population is also expected to propel the growth of the Cyramza (ramucirumab) market in the coming years. An aging population refers to an increasing proportion of older individuals within society, largely due to longer life expectancy and declining birth rates. This demographic shift is primarily driven by improvements in healthcare that have extended average lifespans. Cyramza (ramucirumab) is commonly used among older patients to treat advanced cancers by inhibiting the blood vessel growth that supports tumor development. For instance, in January 2024, according to the Population Reference Bureau, a US-based non-profit organization, the number of Americans aged 65 and older is projected to increase from 58 million in 2022 to 82 million by 2050, representing a 47% rise. Consequently, this age group’s share of the total US population is expected to grow from 17% to 23% over the same period. Therefore, the rise in the aging population is driving the growth of the Cyramza (ramucirumab) market.

Major companies operating in the cyramza (ramucirumab) market are Eli Lilly and Company.

North America was the largest region in the cyramza (ramucirumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cyramza (ramucirumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cyramza (ramucirumab) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the cyramza market by increasing costs associated with monoclonal antibody production inputs and specialized biologics manufacturing equipment. These impacts are strongly felt in oncology hospitals across North America, Europe, and Asia Pacific. Import duties have contributed to higher treatment costs for advanced cancer therapies. Distribution timelines have also been affected due to regulatory and customs delays. However, tariffs are promoting domestic biologics manufacturing and encouraging regional oncology drug production capacity.

The cyramza (ramucirumab) market research report is one of a series of new reports that provides cyramza (ramucirumab) market statistics, including cyramza (ramucirumab) industry global market size, regional shares, competitors with a cyramza (ramucirumab) market share, detailed cyramza (ramucirumab) market segments, market trends and opportunities, and any further data you may need to thrive in the cyramza (ramucirumab) industry. This cyramza (ramucirumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cyramza (ramucirumab) is a monoclonal antibody employed in the treatment of cancer. It functions by targeting and blocking vascular endothelial growth factor receptor 2 (VEGFR-2), thereby inhibiting the formation of blood vessels that supply tumors. It is widely used in the management of several cancers, including gastric, colorectal, and lung cancer.

The main dosage forms of Cyramza (ramucirumab) are 100 mg/box and 500 mg/box. The 100 mg/box option refers to packaging that contains 100 mg of the drug per box and is typically used for patients who require lower doses during cancer treatment. This smaller pack size supports convenient distribution and usage across different healthcare environments. Cyramza is applied in the treatment of advanced gastric cancer, gastroesophageal junction (GEJ) adenocarcinoma, non-small cell lung carcinoma, metastatic colorectal cancer (MCRC), and hepatocellular carcinoma (HCC), and is utilized by end users such as hospitals, cancer treatment centers, ambulatory surgical centers, and research institutes.

The cyramza (ramucirumab) market consists of sales of cyramza (ramucirumab) iv infusion and combination therapy formulations. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.